Article Text

PDF
Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer
  1. Gitte Kristensen1,
  2. Kasper Drimer Berg1,
  3. Solvej Lippert1,
  4. Ib Jarle Christensen2,3,
  5. Klaus Brasso1,
  6. Gunilla Høyer-Hansen2,4,
  7. Martin Andreas Røder1
  1. 1Department of Urology, Rigshospitalet, Copenhagen Prostate Cancer Center, University of Copenhagen, Copenhagen, Denmark
  2. 2Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
  3. 3Department of Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark
  4. 4The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
  1. Correspondence to Dr Gitte Kristensen, Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet 7521, Blegdamsvej 9, Copenhagen 2100 OE, Denmark; gittekristensen1988{at}gmail.com

Abstract

Aims Lymph node metastasis (N1) is an adverse prognostic factor for men with clinically localised prostate cancer (PCa), but the prediction of N1 disease remains difficult. Urokinase plasminogen activator receptor (uPAR) plays an important role in angiogenesis and tumorigenesis. We analysed whether plasma levels of the soluble uPAR forms uPAR(I-III), uPAR(II-III) and uPAR(I) were associated with the risk of N1 disease in men with clinically localised PCa.

Methods The present study includes all men (n=518) who underwent radical prostatectomy (RP) for clinically localised PCa, 29 of whom had N1 disease. Soluble uPAR forms were measured using three time-resolved fluorescence immunoassays. The prognostic value of the different uPAR forms together with clinicopathological parameters for N1 disease were analysed using logistic regression, receiver operating characteristic (ROC) regression analysis and quantified using the areas under the ROC curve (AUC).

Results All soluble uPAR levels were significantly (p=0.03) higher in patients with N1 disease compared with patients with N0/x disease. ROC curves including clinical tumour stage, biopsy Gleason score, prostate-specific antigen and percent positive biopsies had an AUC of 87.7% for prediction of N1 disease. With the addition of uPAR(I) to the model, the AUC increased to 88.4%.

Conclusions Addition of uPAR(I) level to known diagnostic parameters did not increase the prediction of N1 disease following RP in men with clinically localised PCa. Our results indicate that the plasma levels at diagnosis of the different uPAR forms do not hold important predictive or prognostic information in men with clinically localised PCa.

  • Prostate
  • Cancer
  • Diagnostics

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors GK, KDB, SL, KB and MAR designed the study. GK drafted the manuscript which was critically reviewed by KDB, SL, IJC, KB, GH-H and MAR. GH-H, KB and MAR provided study supervision. SL and KDB contributed to data collection. GK and IJC performed data analysis and all authors contributed to data interpretation.

  • Funding The CuPCa database is sponsored by a grant from Jascha Foundation.

  • Competing interests None declared.

  • Ethics approval The study was approved bythe Danish National Committee on Biomedical Research Ethics for the Capital Region (no: H-4-2011-071).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.